Cardinal Health, Inc. (CAH) — Fair Value Analysis

Base-case fair value (P50): $280.65 · Current price: $195.20 · Verdict: Undervalued

The Verdict on CAH

Cardinal Health (CAH) appears significantly undervalued based on our Monte Carlo simulations, with a median fair value (P50) of $280.65. This assessment suggests a substantial +43.8% potential compared to its current price of $195.20. Our analysis points to CAH as a compelling opportunity, distinguishing it from potentially overvalued peers in the broader market. Investors should note this pronounced discrepancy between its current trading price and its intrinsic value derived from thousands of simulated forward-looking scenarios. The "undervalued" verdict for CAH underscores a clear investment thesis driven by robust quantitative modeling.

How CAH stacks up against Healthcare

Within the Healthcare sector, Cardinal Health exhibits a strong quality tier, reflecting solid operational and financial health. This "strong" quality rating supports the positive outlook presented by the +43.8% potential. While many Healthcare stocks may face valuation pressures, CAH's current price of $195.20 relative to its $280.65 fair value indicates it is not only fundamentally sound but also attractively priced. The sector's inherent stability often commands a premium, making CAH's current valuation even more noteworthy given its underlying strength and the substantial upside projected by our simulations.

What this means for investors

For investors considering CAH, the significant +43.8% from $195.20 to the $280.65 median fair value of $280.65 presents a clear directional indicator. This strong valuation gap, coupled with Cardinal Health's "strong" quality tier, suggests a favorable risk/reward profile. Our Monte Carlo simulations, the backbone of FairCurve's methodology, offer a probability-weighted view of potential outcomes, highlighting CAH's intrinsic value. To fully understand the distribution, including our bear-case (P10) and bull-case (P90) price targets, sign up for a free FairCurve account and track CAH's fair value as new fundamentals are released.